Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathog

Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathog

Item

http://www.wikidata.org/entity/Q37520310

Q37520310

about

Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis.Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro.

P2860

Q37619959-238490B4-76FF-46F0-80DE-C77AC5194973 Q55318529-921ADE1E-C5B3-4087-90AA-380FAD31BE52

P2860

Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathog

Item

http://www.wikidata.org/entity/Q37520310

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Morphoproteomics and biomedica ...... rogressing on rapalogs: pathog

@en

Morphoproteomics and biomedica ...... etastatic renal cell carcinoma

@nl

type

Item

label

Morphoproteomics and biomedica ...... rogressing on rapalogs: pathog

@en

Morphoproteomics and biomedica ...... etastatic renal cell carcinoma

@nl

prefLabel

Morphoproteomics and biomedica ...... rogressing on rapalogs: pathog

@en

Morphoproteomics and biomedica ...... etastatic renal cell carcinoma

@nl

P1476

Morphoproteomics and biomedica ...... rogressing on rapalogs: pathog

@en

P2093

Jamie Buryanek

http://www.w3.org/2001/XMLSchema#string

Keri Csencsits-Smith

http://www.w3.org/2001/XMLSchema#string

Mary F McGuire

http://www.w3.org/2001/XMLSchema#string

Robert E Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models

Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.

Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.

Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.

P304

41612-41621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.9508

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Varaha S Tammisetti

P577

2016-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27223432

http://www.w3.org/2001/XMLSchema#string

P932

5173082

http://www.w3.org/2001/XMLSchema#string

Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathog

about

P2860

P2860

Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathog

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932